The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of six formulations under Drugs Prices Control Order (DPCO), 2013 in related notification dated January 23, 2018.
Name of the scheduled formulations are olmesartan medoxomil + amlodipine + hydrochlorothiazide tablet, tiotropium bromide + formoterol fumarate + ciclesonide powder for inhalation, isosobide dinitrate + hydralazine HCl tablet (Sorbitrate HF), olmesartan medoxomil + amlodipine + tablet and metronidazole.
The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form - III of Schedule - II of the DPCO, 2013 through IPDMS.
Any manufacturer intending to discontinue production of said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form -IV of Schedule - II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
The manufacturers not complying with the ceiling price and notes specified shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
Consequent to the issue of ceiling prices of such formulations as specified, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
Name of the scheduled formulations are olmesartan medoxomil + amlodipine + hydrochlorothiazide tablet, tiotropium bromide + formoterol fumarate + ciclesonide powder for inhalation, isosobide dinitrate + hydralazine HCl tablet (Sorbitrate HF), olmesartan medoxomil + amlodipine + tablet and metronidazole.
The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form - III of Schedule - II of the DPCO, 2013 through IPDMS.
Any manufacturer intending to discontinue production of said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form -IV of Schedule - II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
The manufacturers not complying with the ceiling price and notes specified shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
Consequent to the issue of ceiling prices of such formulations as specified, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.